Post #1019251
2026-04-08 06:35 UTC
1/2
"#Lenacapavir, a twice-yearly, long-acting #HIV prevention tool, represents one of the most promising advances towards ending #AIDS [.]. #Gilead has an obligation to ensure that access is not restricted by where people live, who they are, or what their country can pay. [.] this drug’s development was supported by public funding and through the trust of communities who participated in clinical trials, many of them in countries now excluded from affordable access [.]."
https://www.doctorswithoutborders.org/latest/prevention-should-not-be-privilege-msf-calls-gilead-direct-access-lenacapavir
Replies (1)
-
@rebekka_m@fnordon.de 2026-04-08 06:45
2/2 "We call on #Gilead to respond by April 13, 2026 clarifying: 1. Whether you will sell #lenacapavir directly to #MSF? 2. If not, why, given your stated production capacity? 3. If yes, at what price and how soon can delivery begin? The #health of many people depends on your answers to these questions." Via @sham@mastodon.lol |s faboulous newsletter what happened last week in Asia, Africa and the Americas.